Good news · Health & science · 17 November 2026

MHRA approves new cancer treatment for adults

The MHRA has approved retifanlimab for adults with squamous cell carcinoma of the anal canal that is metastatic or recurrent and cannot be removed by surgery. The medicine is administered as an intravenous infusion every four weeks.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved retifanlimab, marketed as ZYNYZ, for the treatment of adults with squamous cell carcinoma of the anal canal. This approval covers patients whose cancer is metastatic or recurrent and cannot be removed by surgery. The decision was granted to Incyte Biosciences UK Ltd on 5 November 2026.

Retifanlimab works by blocking a pathway that helps cancer cells avoid detection by the immune system. It is given as an intravenous infusion lasting about 30 minutes every four weeks. For the first six cycles, it is administered alongside the chemotherapy medicines carboplatin and paclitaxel. In a study of 308 people, the combination of retifanlimab and chemotherapy was more effective than placebo and chemotherapy at delaying cancer progression. Julian Beach, Executive Director, Operations, said: "This approval provides a new treatment option for adults whose cancer cannot be removed by surgery or has spread to other parts of the body or returned to the same area."

The MHRA will continue to monitor the safety and effectiveness of the medicine as it is used more widely. According to the agency, information will be published on the website within 7 days. The approval follows a previous decision for Merkel cell carcinoma dated July 6, 2026.

The original: MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced anal cancer (MHRA, 11 November 2026)

Written by StreetOwl from MHRA’s own announcement. It was drafted by StreetOwl’s own model, every figure and quotation was checked by code against the announcement, and it was read and approved by Michael Rossi before it went up. It says what was announced, not what anyone should do about it.

More StreetOwl news →

← Back to StreetOwl